ONCODAILY MEDICAL JOURNAL

abstract

Evaluation of TP53 Expression in Pediatric B-cell Acute Lymphoblastic Leukemia and Its Correlation With Clinicopathological Profiles

Hasib Tk, Parminder Kaur, Prateek Bhatia, Amita Trehan, Minu Singh

SIOP ASIA 2025
SAUDI ARABIA

Evaluation of TP53 Expression in Pediatric B-cell Acute Lymphoblastic Leukemia and Its Correlation With Clinicopathological Profiles

Author: *Hasib Tk [1], Parminder Kaur, Prateek Bhatia, Amita Trehan, Minu Singh*

Affiliation: *[1] Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India*

Introduction: TP53 is a tumor suppressor gene which impacts tumor progression and prognosis in various cancers. TP53 isoforms regulate key processes like cell cycle arrest and apoptosis. Elevated TP53 expression in B-cell ALL correlates with poor outcomes, making it a potential prognostic marker and therapeutic target. This study aimed to evaluate the expression of TP53 isoforms and its correlation with clinicopathological profiles in pediatric B-cell ALL patients.

Methodology: One hundred pediatric B-cell ALL patients (≤12 years) and 20 age matched healthy controls were enrolled for this study. Expression of TP53 full-length and isoform Delta40TP53, Delta133TP53, TP53 Beta expressions was checked using qRT-PCR. Fold change was calculated using 2- $\Delta\Delta$Ct method. T expression of isoforms was correlated with various clinical parameters such as risk stratification, blast count, molecular cytogenetics etc.

Results: The median age of the patients was 5 years with male: female ratio of 1.2:1. 52% patients had high expression of TP53 full gene expression with the maximum fold change of 9.99-fold. Isoform Delta40TP53, Delta133TP53 and TP53Beta were overexpressed in 17%, 53% and 6% of the patients respectively. Delta133TP53 showed significant association with presence of ETV6::RUNX1 (p=0.047) which is associated with standard risk. The presence of KMT2A::AF4 which is linked with poor prognosis was associated with TP53 Beta expression (p=0.043). However, we could not find a significant association between expression of TP53 isoforms and clinical parameters such as age, gender, MRD or progressive disease in pediatric ALL patients.

Conclusion: Our study has shown that the expression of full length TP53 and its isoforms is dysregulated in Pediatric B-ALL patients. These findings suggest that Delta133TP53 could be further explored as a potential biomarker for standard risk, while TP53Beta might serve as an indicator of poor risk in ALL, warranting further investigation in larger cohorts.